Cited by 2,060Plant biochemistry and biosynthesisMicrobial Metabolic Engineering and BioproductionMicrobial Natural Products and Biosynthesis

High-level semi-synthetic production of the potent antimalarial artemisinin

Open access
Paddon, C. J., Westfall, P. J., Pitera, D. J., Benjamin, K., Fisher, K., McPhee, D., Leavell, M. D., Tai, A. +42 more·2013·Nature

Abstract

In 2010 there were more than 200 million cases of malaria, and at least 655,000 deaths. The World Health Organization has recommended artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated malaria caused by the parasite Plasmodium falciparum. Artemisinin is a sesquiterpene endoperoxide with potent antimalarial properties, produced by the plant Artemisia annua. However, the supply of plant-derived artemisinin is unstable, resulting in shortages and price fluctuations, complicating production planning by ACT manufacturers. A stable source of affordable artemisinin is required. Here we use synthetic biology to develop strains of Saccharomyces cerevisiae (baker's yeast) for high-yielding biological production of artemisinic acid, a precursor of artemisinin. Previous attempts to produce commercially relevant concentrations of artemisinic acid were unsuccessful, allowing production of only 1.6 grams per litre of artemisinic acid. Here we demonstrate the complete biosynthetic pathway, including the discovery of a plant dehydrogenase and a second cytochrome that provide an efficient biosynthetic route to artemisinic acid, with fermentation titres of 25 grams per litre of artemisinic acid. Furthermore, we have developed a practical, efficient and scalable chemical process for the conversion of artemisinic acid to artemisinin using a chemical source of singlet oxygen, thus avoiding the need for specialized photochemical equipment. The strains and processes described here form the basis of a viable industrial process for the production of semi-synthetic artemisinin to stabilize the supply of artemisinin for derivatization into active pharmaceutical ingredients (for example, artesunate) for incorporation into ACTs. Because all intellectual property rights have been provided free of charge, this technology has the potential to increase provision of first-line antimalarial treatments to the developing world at a reduced average annual price.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature12051

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • When three copies of HMGR from A. annua were introduced into S. cerevisiae, significantly more artemisinic acid was produced than from single gene copies.

    “When three copies of HMGR were introduced from A. annua into S. cerevisiae, significantly more artemisinic acid was produced than from single gene copies (Paddon et al. 2013).”

    From Enhancing artemisinin content in and delivery from Artemisia annua: a review of alternative, classical, and transgenic approaches (2021) · cites this paper as Paddon et al. 2013

    The pathway description (Figure 1 caption in the section labelled Abstract; page unavailable) identifies tHMG1 as encoding truncated HMG-CoA reductase. Our copy does not report introducing three copies of A. annua HMGR into yeast or comparing their artemisinic acid production with single-copy strains (searched: HMGR, HMG-CoA reductase, and three copies). (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Paddon, C. J., Westfall, P. J., Pitera, D. J., Benjamin, K., Fisher, K., McPhee, D., Leavell, M. D., Tai, A., Main, A., Eng, D., Polichuk, D. R., Teoh, K. H., Reed, D. W., Treynor, T., Lenihan, J., Jiang, H., Fleck, M., Bajad, S., Dang, G., Dengrove, D., Diola, D., Dorin, G., Ellens, K. W., Fickes, S., Galazzo, J., Gaucher, S. P., Geistlinger, T., Henry, R., Hepp, M., Horning, T., Iqbal, T., Kizer, L., Lieu, B., Melis, D., Moss, N., Regentin, R., Secrest, S., Tsuruta, H., Vazquez, R., Westblade, L. F., Xu, L., Yu, M., Zhang, Y., Zhao, L., Lievense, J., Covello, P. S., Keasling, J. D., Reiling, K. K., Renninger, N. S., & Newman, J. D.
Affiliations
  • Amyris (United States) (US)
  • National Research Council Canada (CA)
  • Lawrence Berkeley National Laboratory (US)
Corresponding author
  • Paddon, C. J.
  • Newman, J. D.
Venue
Nature
Published
2013-04
Volume
496
Issue
7446
Pages
528-532
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W1990226486
Cited by
2,060
References
30
Citations by year
2026: 115 · 2025: 139 · 2024: 164 · 2023: 147 · 2022: 176 · 2021: 176 · 2020: 160 · 2019: 163 · 2018: 176 · 2017: 150 · 2016: 163 · 2015: 144 · 2014: 144 · 2013: 40 · 2012: 2
FWCI
73.36
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • NPARC (submittedVersion)
Funders
  • Bill and Melinda Gates Foundation
  • Sanofi
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Plant biochemistry and biosynthesis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Microbial Metabolic Engineering and Bioproduction
  • Health Sciences › Medicine › Pharmacology › Microbial Natural Products and Biosynthesis
Keywords
artemisinin, artemisinic acid, Saccharomyces cerevisiae, artemisinin biosynthesis, dehydrogenase, cytochromes, singlet oxygen, artemisinin-based combination therapy, malaria treatment, Plasmodium falciparum, industrial fermentation
MeSH terms
Antimalarials, Biotechnology, Fermentation, Genetic Engineering, Molecular Sequence Data, Saccharomyces cerevisiae, Malaria, Falciparum, Singlet Oxygen, Artemisinins, Biosynthetic Pathways

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review